The Will Rogers phenomenon: the effect of different diagnostic criteria

Journal of the Neurological Sciences

Volumn 287, Issue SUPPL. 1, 2009, Pages

  Pia Sormani, Maria ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Clinical trials; Diagnosis; Multiple sclerosis; Prognosis; Stage migration; Will Rogers phenomenon

Indexed keywords

BETA1A INTERFERON; NATALIZUMAB;

ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; SURVIVAL RATE;

DEMYELINATING DISEASES; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS; LUNG NEOPLASMS; MULTIPLE SCLEROSIS; NEOPLASM METASTASIS; PROGNOSIS;

EID: 72649102197     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(09)71300-0     Document Type: Article

References (20)

1. Lublin F.D., and Reingold S.C. Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS. Ann Neurol 49 (2001) 677-681
2. Polman C.H., Reingold S.C., Barkhof F., Calabresi P.A., Clanet M., Cohen J.A., et al. Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology 70 (2008) 1134-1140
3. McFarland H.F., and Reingold S.C. The future of multiple sclerosis therapies: redesigning multiple sclerosis clinical trials in a new therapeutic era. Mult Scler (Houndmills, Basingstoke, England) 11 (2005) 669-676
4. Giovannoni G., Barbarash O., Casset-Semanaz F., King J., Metz L., Pardo G., et al. Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Mult Scler (Houndmills, Basingstoke, England) 15 (2009) 219-228
5. Noseworthy J. The challenge of long-term studies in multiple sclerosis: use of pooled data, historical controls and observational studies to determine efficacy. In: Rudick R., and Cohen J.A. (Eds). Multiple sclerosis therapeutics. 2nd edition (2003), Martin Dunitz, London 319-330
6. Cutter G., Sormani M., Pace A., and Zhang H. Statistical analysis of clinical endpoints in studies of disease-modifying therapies for multiple sclerosis. Neurology 70 Suppl 1 (2008) A104
7. Sormani M.P., Tintore M., Rovaris M., Rovira A., Vidal X., Bruzzi P., et al. Will Rogers phenomenon in multiple sclerosis. Ann Neurol 64 (2008) 428-433
8. Feinstein A.R., Sosin D.M., and Wells C.K. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 312 (1985) 1604-1608
9. Poser C.M., Patya D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13 (1983) 227-231
10. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50 (2001) 121-127
11. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.P., Kappos L., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 58 (2005) 840-846
12. Tintoré M., Rovira A., Rio J., Nos C., Grive E., Sastre-Garriga J., et al. New diagnostic criteria for multiple sclerosis: application in first demyelinating episode. Neurology 60 (2003) 27-30
13. Miller D.H., Barkhof F., and Nauta J.J. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 116 Pt 5 (1993) 1077-1094
14. Filippi M., and Rocca M.A. Conventional MRI in multiple sclerosis. J Neuroimaging 17 Suppl 1 (2007) 3S-9S
15. Dalton C.M., Brex P.A., Miszkiel K.A., Hickman S.J., MacManus D.G., Plant G.T., et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 52 (2002) 47-53
16. Barkhof F., Rocca M., Francis G., Van Waesberghe J.H., Uitdehaag B.M., Hommes O.R., et al. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. Ann Neurol 53 (2003) 718-724
17. Langer-Gould A., Popat R.A., Huang S.M., Cobb K., Fontoura P., Gould M.K., et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol 63 (2006) 1686-1691
18. Polman C.H., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354 (2006) 899-910
19. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352 (1998) 1498-1504
20. Tintoré M. Rationale for early intervention with immunomodulatory treatments. J Neurol 255 Suppl 1 (2008) 37-43